| Cambium Bio Limited (CMB) ORDINARY FULLY PAID |
Health Care |
$12 |
Cambium Bio Signs Manufacturing MOU with Locus Cell
|
30 Sep 2025 1:32PM |
$0.520 |
$0.440 |
fallen by
15.38%
|
|
| Cambium Bio Limited (CMB) ORDINARY FULLY PAID |
Health Care |
$12 |
Proposed issue of securities - CMB
|
15 Sep 2025 10:31AM |
$0.510 |
$0.440 |
fallen by
13.73%
|
|
| Cambium Bio Limited (CMB) ORDINARY FULLY PAID |
Health Care |
$12 |
Notice of Annual General Meeting and Proxy form
|
15 Sep 2025 10:27AM |
$0.510 |
$0.440 |
fallen by
13.73%
|
|
| Cambium Bio Limited (CMB) ORDINARY FULLY PAID |
Health Care |
$12 |
Cambium Bio Signs Strategic MoU with Benta SAS
|
5 Sep 2025 11:37AM |
$0.465 |
$0.440 |
fallen by
5.38%
|
|
CMB - Price-sensitive ASX Announcement
Full Release
Key Points
- Cambium Bio signs MoU with Benta SAS.
- Exclusive commercialization rights for Elate Ocular® in Europe and Middle East.
- Partnership involves technology transfer and potential joint venture.
- Benta SAS has extensive experience in blood-derived therapeutics.
- This is the second licensing deal in three days for Cambium's technology.
- Definitive agreements execution and regulatory submissions planned within four months.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cambium Bio Limited (CMB) ORDINARY FULLY PAID |
Health Care |
$12 |
Cambium Bio Signs US$2.0M plus Licensing Deal
|
2 Sep 2025 1:07PM |
$0.465 |
$0.440 |
fallen by
5.38%
|
|
CMB - Price-sensitive ASX Announcement
Full Release
Key Points
- Cambium Bio signs a US$2.0M+ licensing deal with Keke Medtech.
- The deal covers developing a fibrin biologic for dental and oral applications.
- Financial terms include US$250,000 upfront and US$1.75 million in milestones.
- Royalties on net sales are set at 10% for the first US$10M annually, then 13%.
- The agreement is for US, Southeast Asia, Middle East, and Taiwan.
- Keke will finance all related development costs.
- Cambium retains focus on their Elate Ocular® Phase 3 program.
- The deal provides strategic validation and non-dilutive funding.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cambium Bio Limited (CMB) ORDINARY FULLY PAID |
Health Care |
$12 |
FY25 Appendix 4G and Corporate Governance Statement
|
29 Aug 2025 4:00PM |
$0.470 |
$0.440 |
fallen by
6.38%
|
|
| Cambium Bio Limited (CMB) ORDINARY FULLY PAID |
Health Care |
$12 |
FY25 Appendix 4E and Annual Report
|
29 Aug 2025 3:56PM |
$0.470 |
$0.440 |
fallen by
6.38%
|
|
CMB - Price-sensitive ASX Announcement
Full Release
Key Points
- Loss after income tax of $3.84 million for the year ended 30 June 2025.
- Accumulated losses totaled $46.59 million.
- Total equity amounted to $1.84 million.
- Revenue primarily from royalty income in the USA.
- Significant expenses in research and development and corporate operations.
- Share issuance and share-based payments were key financial activities.
- Executive remuneration and shareholder information detailed.
- Focus on biotechnology innovations and strategic financial management.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cambium Bio Limited (CMB) ORDINARY FULLY PAID |
Health Care |
$12 |
FY25 Appendix 4E and Annual Report
|
29 Aug 2025 3:56PM |
$0.470 |
$0.440 |
fallen by
6.38%
|
|
CMB - Price-sensitive ASX Announcement
Full Release
Key Points
- Cambium Bio Limited reported a revenue of $670,000 for the year ending 30 June 2025, a 419% increase from the previous year.
- The company recorded a net loss of $3.844 million, a 70% increase in loss compared to the previous year.
- No dividends were paid or proposed for the year.
- Audited by Stantons International Audit and Consulting Pty Ltd.
- The company announced a fully-subscribed A$2.12 million placement to fund the Phase 3 program.
- Key management personnel remuneration included both fixed salaries and a short-term incentive program.
- Total assets decreased from $4.47 million in 2024 to $1.76 million in 2025.
- Shareholder equity fell from $2.82 million to $1.16 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cambium Bio Limited (CMB) ORDINARY FULLY PAID |
Health Care |
$12 |
Cleansing notice
|
29 Aug 2025 9:23AM |
$0.440 |
$0.440 |
fallen by
0%
|
|
| Cambium Bio Limited (CMB) ORDINARY FULLY PAID |
Health Care |
$12 |
Application for quotation of securities - CMB
|
29 Aug 2025 9:21AM |
$0.440 |
$0.440 |
fallen by
0%
|
|
| Cambium Bio Limited (CMB) ORDINARY FULLY PAID |
Health Care |
$12 |
Update - Proposed issue of securities - CMB
|
27 Aug 2025 11:35AM |
$0.360 |
$0.440 |
risen by
22.22%
|
|
| Cambium Bio Limited (CMB) ORDINARY FULLY PAID |
Health Care |
$12 |
Placement Participant Update
|
27 Aug 2025 11:27AM |
$0.360 |
$0.440 |
risen by
22.22%
|
|
CMB - Price-sensitive ASX Announcement
Full Release
Key Points
- Cambium Bio Limited announces an update to its placement participants.
- Certain institutional and sophisticated investors have been added and removed as placement participants.
- There is no change to the total amount of funds raised or the terms of the placement.
- The update is for transparency and compliance with ASX Listing Rules.
- The announcement does not affect the overall outcome or objectives of the placement.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cambium Bio Limited (CMB) ORDINARY FULLY PAID |
Health Care |
$12 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 Jul 2025 11:39AM |
$0.460 |
$0.440 |
fallen by
4.35%
|
|
CMB - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly Activities and Appendix 4C Cash Flow Report released for the quarter ending 31 March 2024.
- Progress made on the lead program in Targeted Protein Degradation (TPD) focused on oncology.
- Ongoing research collaboration with Servier, with milestones achieved during the quarter.
- Development of the in-house asset pipeline continues with new opportunities being explored.
- Financial summary shows the Company’s cash movements and closing balance at the end of the quarter.
- No significant changes to related party transactions were reported.
- The Company is actively considering capital management options to support future operations and strategic initiatives.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cambium Bio Limited (CMB) ORDINARY FULLY PAID |
Health Care |
$12 |
Proposed issue of securities - CMB
|
30 Jul 2025 11:14AM |
$0.290 |
$0.440 |
risen by
51.72%
|
|
| Cambium Bio Limited (CMB) ORDINARY FULLY PAID |
Health Care |
$12 |
Cambium Bio Raises A$2.12 million
|
30 Jul 2025 11:14AM |
$0.290 |
$0.440 |
risen by
51.72%
|
|
CMB - Price-sensitive ASX Announcement
Full Release
Key Points
- Cambium Bio Limited raised A$2.12 million via a placement to sophisticated and professional investors.
- Funds will be used to advance cell-based therapeutics in regenerative medicine and tissue engineering.
- The capital supports further development of lead product candidates.
- Funding will facilitate ongoing clinical and preclinical programs.
- Proceeds will assist with regulatory submissions and expansion of R&D activities.
- The placement was well supported, reflecting investor confidence in Cambium Bio’s strategy and prospects.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cambium Bio Limited (CMB) ORDINARY FULLY PAID |
Health Care |
$12 |
Cambium Bio Clears FDA Regulatory Hurdles
|
11 Jul 2025 9:10AM |
$0.215 |
$0.440 |
risen by
104.65%
|
|
| Cambium Bio Limited (CMB) ORDINARY FULLY PAID |
Health Care |
$12 |
Cambium Bio Receives Ethics Approvals
|
30 Jun 2025 9:23AM |
$0.210 |
$0.440 |
risen by
109.52%
|
|
| Cambium Bio Limited (CMB) ORDINARY FULLY PAID |
Health Care |
$12 |
Change of Address
|
23 May 2025 3:56PM |
$0.190 |
$0.440 |
risen by
131.58%
|
|
| Cambium Bio Limited (CMB) ORDINARY FULLY PAID |
Health Care |
$12 |
Initial Director's Interest Notice - Denese Marks
|
22 May 2025 4:36PM |
$0.190 |
$0.440 |
risen by
131.58%
|
|
| Cambium Bio Limited (CMB) ORDINARY FULLY PAID |
Health Care |
$12 |
Final Director's Interest Notice - Barry Sechos
|
22 May 2025 4:35PM |
$0.190 |
$0.440 |
risen by
131.58%
|
|
| Cambium Bio Limited (CMB) ORDINARY FULLY PAID |
Health Care |
$12 |
Board and Company Secretary Changes
|
21 May 2025 12:32PM |
$0.190 |
$0.440 |
risen by
131.58%
|
|
| Cambium Bio Limited (CMB) ORDINARY FULLY PAID |
Health Care |
$12 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 Apr 2025 9:55AM |
$0.290 |
$0.440 |
risen by
51.72%
|
|
CMB - Price-sensitive ASX Announcement
Full Release
Key Points
- FDA approved Phase 3 clinical trial protocol on 25 February 2025.
- Cambium raised A$2.0 million from a capital raise completed in March 2025.
- The company held cash reserves of A$1.393 million as of 31 March 2025.
- Net operating cash outflow was A$1.1 million due to R&D investments.
- Upcoming milestones include finalizing clinical drug product manufacturing and initiating global out-licensing discussions for Elate Ocular®.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Cambium Bio Limited (CMB) ORDINARY FULLY PAID |
Health Care |
$12 |
Change of registry address
|
14 Apr 2025 5:07PM |
$0.280 |
$0.440 |
risen by
57.14%
|
|
| Cambium Bio Limited (CMB) ORDINARY FULLY PAID |
Health Care |
$12 |
Notice of ceasing to be a substantial holder
|
11 Apr 2025 3:05PM |
$0.280 |
$0.440 |
risen by
57.14%
|
|
| Cambium Bio Limited (CMB) ORDINARY FULLY PAID |
Health Care |
$12 |
Cambium Bio - Release of Shares from Escrow
|
21 Mar 2025 6:38PM |
$0.350 |
$0.440 |
risen by
25.71%
|
|
Call 1300 880 160
Start a chat
Schedule a call
